1. ALLA AKTIER
  2. NYHETER
  3. PROSTALUND

ProstaLund

Nyheter ProstaLund Nyheter alla bolag

A strong finish with several new agreements

MAR

Rapid sales growth outside the Nordics, accounted for 11% of sales in the last quarter

1 January-31 December

  • Net sales reached SEK 17,4 (17,1) million
  • Loss after taxes SEK -11,1 (-7,9) million
  • Earnings per share were SEK -0,21 SEK (-0,17)
  • Cash and equivalents were 12,3 (13,2) million
  • The board proposes that no dividend be paid to the company's shareholders

Significant events during period

  • Distribution agreement signed for Spain
  • Distribution agreement signed for China
  • Distribution agreement signed for Italy
  • Results for the registry study on prostate cancer were presented at the Urology Days by one of the authors
Key figures


(SEK MILLION)Jan-Dec
2022		Jan-Dec
2021		Jan-Dec
2020
Net sales17,417,112,5
Gross margin, %758677
Operating profit/loss-10,9-7,9-9,9
Cash flow from operating activities-16,2-5,8-8,6
Average number of employees876

1 October-31 December

  • Net sales increased 12% to SEK 5,5 (4,9) million
  • Loss after taxes SEK -3,1 (-2,2) million
  • Earnings per share were SEK -0,05 SEK (-0,04)

Significant events after the end of the period

  • Study on the Schelin Catheter is published
  • CE-mark for the new platform Eagle obtained
  • Patent that include the Schelin Catheter is approved
  • Agreement with Sergelkliniken is signed
  • Agrement with Carlshamns Specialist klinik is signed
  • Agreement with SLG Kalmar is signed with an order value of at least SEK 2,4 million


” The network of contacts and the interest that we have created among the world's
urologists during the last six months will be very valuable going forward.”

Johan Wennerholm
CEO, ProstaLund AB (publ)

Please see attached PDF for full report.

For further information, please contact:

Johan Wennerholm,  CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company’s lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-15 08:15 CET.

Attachments

ProstaLund AB (publ) Year End Report Jan Dec 2022

Datum 2023-02-15, kl 08:15
Källa MFN
Bifogade filer
ProstaLund AB (publ) Year End Report Jan Dec 2022
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.